Rise Therapeutics

Yesterday our team partnered with Montgomery County Economic Development Corporation - Maryland and Maryland Department of Commerce to visit Rise Therapeutics, an innovative biotechnology company in Rockville developing leading-edge treatments for inflammation, autoimmune diseases and cancer using proprietary oral biologics! 📍🧬 💡Discover more about Rise Therapeutics innovative microbiome-based immune therapies at https://lnkd.in/ew7ZNVGm

We are thrilled to share that Gary Fanger, Chief Executive Officer, from Rise Therapeutics, will be presenting as an Expert Speaker at the 9th Microbiome Movement Drug Development Summit, taking place in Boston, US, from 10 to 12 July. He will also contribute to a panel discussion entitled “Defining Innovative Clinical Strategies Conserving Spend” on July 12th at 9:30 AM at the conference. Download the agenda here: https://lnkd.in/gC3VQTXp #MicrobiomeMovement #Microbiome

We are excited to share that Janet Stephens PhD at Rise Therapeutics is on the panel for the 2024 Mountain West BioLife Summit. This summit explores the topics of clinical trial development. You do not want to miss the engaging discussions on key points of clinical trial development from venues and vendors to protocol creation, and more.

FDA Clears Rise Therapeutics’ IND Application to Initiate a Phase 1 Clinical Study of Its Novel Oral Immunotherapy for the Treatment of Rheumatoid Arthritis Rockville, Maryland, October 19, 2023 – Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a rheumatoid arthritis Phase 1 clinical trial for its program candidate, R-2487. This is Rise Therapeutics’ second clinical program developed using synthetic biology and its proprietary oral biologics delivery platform. Designed specifically to induce regulatory T cells (Tregs) and reset immune balance in patients suffering from autoimmunity, R-2487 works by educating dendritic cells to redirect immune responses away from inflammatory effects. R-2487 is a cellular immunotherapy being developed for the treatment of rheumatoid arthritis, engineered to treat the underlying immunological basis of autoimmune disease. Consequently, R-2487 has the potential to target the root cause of rheumatoid arthritis and reverse the development of this devastating disease.   “We are extremely excited to initiate our second clinical-stage program at Rise Therapeutics with the evolution of R-2487” states Gary Fanger, President and CEO of Rise Therapeutics. “As we grow our clinical development infrastructure, our plan is to clinically validate a series of life-saving medications based upon our synthetic biology platform technology to evolve oral immunotherapy approaches that both improve the ease of delivery of protein-based biologics therapy and reduce the cost of these important immune regulatory-based medicines. We believe R-2487 has the potential to broadly treat autoimmune diseases.” The Phase I clinical trial will be a single and repeat dose study assessing the safety and tolerability, drug exposure, and clinical activity of R-2487 in patients with rheumatoid arthritis. The study will enroll up to 36 participants where the clinical activity of R-2487 will be evaluated by improvement in rheumatoid arthritis disease severity, and by measuring a variety of key biomarker and pharmacodynamic assessments. Press Release: https://lnkd.in/ezr4WSn2

FDA Clears Rise Therapeutics’ IND Application to Initiate a Phase 1 Clinical Study of Its Novel Oral Immunotherapy for the Treatment of Rheumatoid Arthritis Rockville, Maryland, October 19, 2023 – Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a rheumatoid arthritis Phase 1 clinical trial for its program candidate, R-2487. This is Rise Therapeutics’ second clinical program developed using synthetic biology and its proprietary oral biologics delivery platform. Designed specifically to induce regulatory T cells (Tregs) and reset immune balance in patients suffering from autoimmunity, R-2487 works by educating dendritic cells to redirect immune responses away from inflammatory effects. R-2487 is a cellular immunotherapy being developed for the treatment of rheumatoid arthritis, engineered to treat the underlying immunological basis of autoimmune disease. Consequently, R-2487 has the potential to target the root cause of rheumatoid arthritis and reverse the development of this devastating disease.   “We are extremely excited to initiate our second clinical-stage program at Rise Therapeutics with the evolution of R-2487” states Gary Fanger, President and CEO of Rise Therapeutics. “As we grow our clinical development infrastructure, our plan is to clinically validate a series of life-saving medications based upon our synthetic biology platform technology to evolve oral immunotherapy approaches that both improve the ease of delivery of protein-based biologics therapy and reduce the cost of these important immune regulatory-based medicines. We believe R-2487 has the potential to broadly treat autoimmune diseases.” The Phase I clinical trial will be a single and repeat dose study assessing the safety and tolerability, drug exposure, and clinical activity of R-2487 in patients with rheumatoid arthritis. The study will enroll up to 36 participants where the clinical activity of R-2487 will be evaluated by improvement in rheumatoid arthritis disease severity, and by measuring a variety of key biomarker and pharmacodynamic assessments. Press Release: https://lnkd.in/ezr4WSn2